Vaccine Safety

 

Vaccine Safety

 

With the ever-increasing volume in data and a growing number of new vaccines entering the market it has never been more important to leverage new technologies and methods to improve the efficiency and accuracy of pharmacovigilance for vaccines.  

This focussed vaccine safety and pharmacovigilance conference will allow you to listen and learn from key thought leaders in this space, as well as to showcase any solutions that are greatly needed in order to revolutionise and replace outdated ways of working.   Furthermore, escalating incidences of vaccine-refusal makes the importance of effective communication paramount, so join us to present your most successful strategies

 

2018 AGENDA 

 

Vaccine Safety & Pharmacovigilance, Wednesday 4 April 2018

International Vaccine Safety

Vaccine Safety & Pharmacovigilance
10:10

What will the impact of EudraVigilance be on launching new vaccine products in Europe from 2018 onwards?

10:40

Networking coffee break

Panel discussion

Methods In Pharmacovigilance

Vaccine Safety & Pharmacovigilance
12:40

Tools for clinical data visualization that improve efficacy and accuracy of safety assessment and allow firms to keep up with changing regulatory requirements

1:10

Networking Lunch & Poster Session

Vaccine Safety & Pharmacovigilance
2:40

New techniques to overcome challenges in pre-clinical safety assessment of vaccines

Dr Jens-Ulrich Stegmann
Vaccine Safety & Pharmacovigilance
3:10

Safety assessment during the clinical development phase of a vaccine

  • Capturing of data
  • Relevance of causality assessment
  • When to build a benefit/risk assessment
  • Different populations vs different approaches
4:10

Networking coffee break

Dr Karen Broder
Vaccine Safety & Pharmacovigilance
4:40

CDC’s post-licensure vaccine safety monitoring systems – addressing 21st century public health needs

  • The Centers for Disease Control and Prevention (CDC) conducts post-licensure vaccine safety monitoring of licensed vaccines in U.S. children, adolescents and adults.
  • The three CDC post-licensure monitoring systems are the Vaccine Adverse Event Reporting System (VAERS), Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) Project. The functions of these systems complement each other and include passive surveillance (VAERS), active surveillance (VSD), clinical and epidemiologic research (VSD and CISA), and individual patient-level clinical case vaccine safety evaluations (CISA).
  • Overview of CDC’s post-licensure vaccine monitoring systems and describe some examples of how the systems have worked together to advance our understanding of vaccine safety.

Interactive Discussion – Mandating Vaccination

6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 12/Dec/17 18:15

Vaccine Safety & Pharmacovigilance, Thursday 5 April 2018

Case Studies In Vaccine Safety

Dr Ashley Wivel
Vaccine Safety & Pharmacovigilance
09:10

Ensuring safety during outbreaks; the EBOLA experience

  • Challenges in vaccine clinical trials during public health emergencies
  • Ebola case study
Dr Neal Halsey
Vaccine Safety & Pharmacovigilance
09:40

The science of causality assessment

  • The science of causality assessment is poorly understood by healthcare providers and the general public
  • Temporal relationships and hypotheses regarding mechanisms are not sufficient to establish causality
  • Journals should establish standard criteria for publishing case reports of alleged causal relationships
  • Decisions to compensate for alleged vaccine injuries should be based on science
  • Safety profiles may vary in different populations
  • All countries should have formal vaccine safety programs
10:40

Networking coffee break

Dr Saad B Omer
Vaccine Safety & Pharmacovigilance
11:30

Safety assessment, communication of risk and interventions around acceptance in maternal immunization

  • Safety of TDaP and IIV vaccine
  • Emerging issues around 1st trimester vaccination, adverse outcomes and how this has informed acceptance
Dr Daniel Salmon
12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 12/Dec/17 18:15

 

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071